Development of a new delivery system consisting in 'drugin cyclodextrinin PLGA nanoparticles'

Journal of Microencapsulation

Volumn 27, Issue 6, 2010, Pages 479-486

  Mura, Paola ^a   Maestrelli, Francesca ^a   Cecchi, Matteo ^a   Bragagni, Marco ^a   Almeida, Antonio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Cyclodextrin complexation; Oxaprozin; PLGA nanoparticles

Indexed keywords

BETA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; NANOPARTICLE; OXAPROZIN; POLYGLACTIN;

ARTICLE; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; PARTICLE SIZE; SOLID STATE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLODEXTRINS; DRUG CARRIERS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; PROPIONIC ACIDS;

EID: 77955454025     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040903515508     Document Type: Article

References (24)

1. Couvreur P, Dubemet C, Puisieux F. 1995. Controlled drug delivery with nanoparticles: Current possibilities and future trends. Eur J Pharm Biopharm 41:2-13.
2. Elkheshen SA, Ahmed SM, Al-Quadeib BT. 2002. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin: in vitro and in vivo drug availability. Pharm Ind 64:708-715.
3. Filipović-Grc̃ić J, Bećirević- Laćan M, S̃kalko N, Jals̃enjak I. 1996. Chitosan microspheres of nifepidine and nifepidine-cyclodextrin inclusion complex. Int J Pharm 135:183-190.
4. Filipović-Grc̃ić J, Voinovich D, Moneghini M, Bećirević-Laćan M, Magarotto L, Jalssenjak I. 2000. Chitosan microspheres with hydrocortisone and hydrocortisone-hydroxypropyl- β-cyclodextrin inclusion complex. Eur J Pharm Sci 9:373-379.
5. Gomez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. 2007. Encapsulation of dexamethasone into biodegradable polymeric nano-particles. Int J Pharm 331:153-159.
6. Hans ML, Lowman AM. 2002. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319-327.
7. Hausberger AG, DeLuca PP. 1995. Characterization of biodegradable poly(lactide-co-glycolide) polymers and microspheres. J Pharm Biomed Anal 13:747-760.
8. Imai T, Irie T, Otagiri M, Uekama K, Yamasaki M. 1984. Comparative study on complexations of antiinflammatory drug flurbiprofen with β-cyclodextrin and methylated β-cyclodextrins. J Inclusion Phenom Macrocyc Chem 2:597-604.
9. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. 2001. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775-781.
10. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. 2005. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 315:196-202.
11. Loftsson T, Duchẽne D. 2007. Cyclodextrins and their therapeutic applications. Int J Pharm 329:1-11.
12. Maestrelli F, Cecchi M, Cirri M, Capasso G, Mennini N, Mura P. 2009. Comparative study of oxaprozin complexation with natural and chemically modified cyclodextrins in solution and in the solid state. J Inclusion Phenom Macrocyc Chem 63:17-25.
13. Maestrelli F, García-Fuentes M, Mura P, Alonso MJ. 2006. A new drug nanocarrier consisting of chitosan and hydroxypropylcyclodextrin. Eur J Pharm Biopharm 63:79-86.
14. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. 2008. Microspheres for colonic delivery of ketoprofen-hydroxypropyl-ß-cyclodextrin complex. Eur J Pharm Sci 34:1-11.
15. Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 290:137-144.
16. Meissner Y, Pellequer Y, Lamprecht A. 2006. Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int J Pharm 316:138-143.
17. Otero Espinar FJ, Anguiano Igea S, Blanco Mendez J, Vila Jato JL. 1991. Reduction in the ulcerogenicity of naproxen by complexation with ß-cyclodextrin. Int J Pharm 70:35-41.
18. Paulus HE. 1995. Actions and toxicity of non-steroidal antiinflammatory drugs. Curr Opin Rheumatol 7:159-166.
19. Reddy KVK, Rao DS, Vyas K, Reddy GO. 2000. LC method for the quantitative determination of oxaprozin and its impurities in the bulk drug. J Pharm Biomed Anal 22:651-659.
20. Rothstein R. 1998. Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 105:39-43.
21. Sashmal S, Mukherjee S, Ray S, Thakur R, Ghosh LK, Gupta BK. 2007. Design and optimization of NSAID loaded nanoparticles. Pakistan J Pharm Sci 20:157-162.
22. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q. 2008. Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 69:445-453.
23. Uekama K, Hirayama F, Tetsumi I. 1998. Cyclodextrin drug carrier systems. Chem Rev 98:2045-2076.
24. Yang S, Zhu J, Lu Y, Liang B, Yang C. 1999. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751-762.